Hyaluronic Acid Knee Injections: Common Billing Errors Medicare Providers Should Address

A Recent Noridian Billing Alert Highlights Common Denial Risks for Injectable Drug Claims

For orthopedic practices and providers billing hyaluronic acid knee injections, a recent update from Noridian Medicare Part B serves as an important reminder: even medically necessary services can face denials when billing, coding, or documentation requirements are not met.

Noridian recently identified several recurring billing errors related to hyaluronic acid knee injections, including incorrect billing units, modifier misuse, insufficient documentation, and coding inaccuracies. While these issues may seem minor, they can result in claim denials, payment delays, audits, and lost revenue.

For practices serving Medicare beneficiaries, now is a good time to review injectable drug billing processes and ensure compliance with current Medicare guidelines.

What Noridian Identified

According to Noridian, the most common issues include:

Incorrect Billing Units

The number of units billed must accurately reflect the dosage administered and the billing requirements for the specific product used.

Errors often occur when:

Billing units do not match the dosage administered
Single-dose and multi-dose vial requirements are confused
Drug-specific billing guidelines are overlooked

Modifier Misuse

Noridian specifically reminded providers that the JW modifier should not be reported for multi-dose vials.

Incorrect modifier usage remains a common reason for claim rejections and denials. Practices should verify appropriate use of:

JW Modifier = Indicates the amount of a single-dose drug that was discarded and eligible for billing.
JZ Modifier = Indicates that no amount of the drug was discarded from a single-dose container.
Drug administration modifiers when applicable

Insufficient Documentation

Medical records must clearly support the service billed.

Documentation should include:

Patient diagnosis
Medical necessity
Prior treatment history
Clinical rationale for selecting hyaluronic acid therapy
Details of the drug administered

Coding Inaccuracies

Providers should verify that the correct HCPCS code is reported for the specific product administered and that any required modifiers are included.

Even small coding errors can create payment delays and increase audit risk.

Recommended Action Steps for Practices

Noridian recommends that providers:

Verify billing units prior to claim submission
Confirm HCPCS code accuracy
Review modifier usage requirements
Ensure documentation supports medical necessity
Conduct internal audits of injectable drug billing processes

Regular billing reviews can help reduce denials, improve reimbursement accuracy, and identify potential compliance risks before they become larger issues.

How Peregrine Healthcare Helps

At Peregrine Healthcare, we help physician practices identify billing vulnerabilities before they impact revenue. Our team works with specialty practices to review coding accuracy, documentation workflows, denial trends, and revenue cycle performance.

For practices administering injectable therapies, even small billing errors can create significant reimbursement challenges over time.

Request a Complimentary Revenue Cycle Review

If your practice bills Medicare for injectable medications and would like an outside review of your billing processes, Peregrine Healthcare offers complimentary revenue cycle assessments to help identify opportunities for improvement.

877-463-1110
peregrinehealthcare.com/contact-us